Montek (Pertechnetate (99mtc) Sodium)

Technetium-99m Pertechnetate mimics iodide and is taken up by cells that express the sodium‑iodide symporter, such as thyroid follicular cells, gastric mucosal cells, and renal tubular cells. Once localized, the radionuclide emits gamma photons that are detected by imaging equipment, producing a visual map of tissue perfusion and tracer distribution.

The administered activity of Montek is determined by the prescribing physician or nuclear medicine specialist based on the specific diagnostic study, patient weight, and institutional protocols. Dosage is calculated to provide sufficient image quality while minimizing radiation exposure, and it is not standardized across all indications.

The safety of Montek in pregnant or breastfeeding individuals has not been definitively established. Because it involves ionizing radiation, it is generally avoided unless the diagnostic benefit outweighs the potential risk to the fetus or infant. Clinicians should discuss alternatives and obtain informed consent when considering use in these populations.

To order Montek, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Montek (Technetium-99m Pertechnetate) offers rapid imaging, lower radiation dose, and high-quality gamma emission compared with iodine‑131 or iodine‑123 compounds. It provides excellent thyroid uptake visualization without the beta radiation associated with iodine‑131, making it preferable for diagnostic scans where therapeutic radiation is not desired.

Montek should be stored at 2‑8 °C in a refrigerator, protected from light, and kept in its original container. It must not be frozen or shaken, as physical agitation can affect the radiochemical stability. Follow local regulations for handling radioactive materials and use appropriate shielding during preparation.

Montek is supplied as a sterile solution for injection and is administered intravenously or, for ocular studies, as a small volume injection into the appropriate ocular tissue. The administration is performed by qualified nuclear medicine personnel under aseptic conditions, with the prescribed activity calculated for the specific diagnostic procedure.

Serious risks include rare allergic reactions such as anaphylaxis, severe hypotension, and radiation‑induced tissue injury. Patients with compromised thyroid function or those who have recently received other radiopharmaceuticals may be at higher risk. Immediate medical attention is required if signs of a severe reaction occur.

Montek should be avoided in individuals with known hypersensitivity to technetium compounds, those who have received high‑dose iodine‑containing contrast agents within the preceding 24 hours, and patients for whom the radiation exposure outweighs the diagnostic benefit, such as certain pregnant women or young children without a clear indication.